This study is exploring the safety of a medication called Seladelpar in people with a liver condition called Primary Biliary Cholangitis (PBC). PBC is a disease where the body's immune system mistakenly attacks the bile ducts in the liver. The study focuses on how safe Seladelpar is for long-term use and how well it works. Participants will also report on any itching they experience, which is a common symptom of PBC.

To join, participants must have been in a previous PBC study with Seladelpar and agree to use birth control if they can have children. People with other serious health conditions, like cancer or certain infections, cannot participate. Also, those with certain liver test results that are too high, or those taking certain medicines, might not be eligible.

• Long-term study with regular check-ups
• Participants must have been in a past Seladelpar study
• Safety and health will be closely monitored